Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis-Reference-Cited by-同舟云学术

Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis

Published:2021-07-30 Issue:2 Volume:195 Page:244-248
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Pardanani Animesh¹^ORCID,Tefferi Ayalew¹^ORCID,Masszi Tamás²,Mishchenko Elena³,Drummond Mark⁴,Jourdan Eric⁵,Vannucchi Alessandro⁶,Jurgutis Mindaugas⁷,Ribrag Vincent⁸,Rambaldi Alessandro⁹¹⁰,Koh Liang Piu¹¹,Rose Shelonitda¹²,Zhang Jun¹²,Harrison Claire¹³

Affiliation:

1. Mayo Clinic of Rochester Rochester MN USA

2. Department of Internal Medicine and Haematology Semmelweis University Budapest Hungary

3. Lady Davis Medical Center Haifa Israel

4. Beatson Cancer Centre University of Glasgow Glasgow UK

5. CHU Caremeau Nimes France

6. University of Florence AOU Careggi Florence Italy

7. Klaipeda Jurininku Hospital Klaipeda Lithuania

8. Institut Gustave Roussy Villejuif France

9. Department of Oncology and Hematology University of Milan MilanItaly

10. Azienda Socio Sanitaria Territorial Papa Giovanni XXIII Bergamo Italy

11. National University Hospital Singapore Singapore Singapore